FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ondansetron (Zofran) Injection
Status: Discontinuation
»Therapeutic Categories: Gastroenterology; Oncology

Novartis (Revised 10/30/2015)

Company Contact Information:
888-825-6682

Presentation Posting Date Related Information
Zofran Injection (Ondasetron Hydrochloride) 2 mg/mL (20-mL multidose vials)(NDC 0173-0442-00) 10/30/2015 The decision to discontinue this product is business-related and not based on efficacy or safety findings.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English